Jefferies has shifted its rating on Cigna from Buy to Hold, citing an accumulation of earnings headwinds and limited upside catalysts that, in the broker's view, outweigh the stock's discounted price multiple. The firm also lowered its price target to $307 from $336.
Earnings outlook and estimate revision
In revising its view, Jefferies trimmed its 2027 earnings-per-share estimate on Cigna to $32.77, a level the firm notes is roughly 1% below consensus. The brokerage said that consensus expectations for 2027 still appear overly optimistic given several outstanding uncertainties, chief among them the strategic review of both EviCore and Cigna's health insurance exchange (HIX) operations.
Potential impacts from EviCore and HIX outcomes
Jefferies warned that if a sale or wind-down of EviCore or the HIX business were to occur, the company could face a meaningful earnings shortfall. The firm estimates that EviCore currently contributes between $700 million and $1 billion in adjusted operating income, or about $2.20 to $3.10 of EPS. Jefferies also cautioned that share repurchases would likely not fully offset any earnings dilution resulting from a divestiture. Along with stranded costs associated with exiting the HIX business, these factors could lower 2027 adjusted operating income by roughly 10% versus current consensus expectations.
GLP-1 coverage and PBM profitability
Jefferies expects headwinds from weight-loss GLP-1 drugs to become more pronounced in 2027. Management has disclosed a $20 million-per-quarter headwind beginning in the second half of 2026; Jefferies further projects that additional employer reductions in coverage could raise the 2027 earnings impact to approximately $126 million. That pressure is expected to weigh on the profitability of Cigna's pharmacy benefit services business.
Broader PBM-related risks
Beyond GLP-1 exposure, Jefferies identified other threats to the PBM franchise, including declining membership at key pharmacy benefit clients such as Medicaid, health insurance exchange and Medicare Part D plans. The brokerage also highlighted a wave of state-level legislation addressing PBM pricing, transparency and ownership structures. Jefferies warned these developments could constrain margin expansion and create a longer-term overhang for the PBM business model.
Valuation and execution considerations
While acknowledging that Cigna currently trades at a depressed valuation of roughly 8.3 times consensus 2027 earnings, Jefferies argued that the discount is justified. The firm cited weaker growth prospects, a lack of clear catalysts to drive multiple expansion and persistent execution risks as Cigna transitions to a rebate-free PBM model.
Key takeaways
- Jefferies downgraded Cigna to Hold and cut its price target to $307 from $336.
- The firm lowered its 2027 EPS estimate to $32.77, about 1% below consensus.
- Material earnings risk centers on the strategic review of EviCore and the HIX business, potential GLP-1 coverage reductions, and regulatory pressure on PBMs.
Risks and uncertainties
- Sale or wind-down of EviCore and exit-related stranded costs at HIX could reduce 2027 adjusted operating income by roughly 10% versus consensus, affecting insurance and PBM-related revenues.
- Further reductions in employer GLP-1 coverage could increase the 2027 earnings impact to about $126 million, pressuring pharmacy benefit services profitability.
- Declining membership at key PBM clients and state-level legislation targeting PBM pricing, transparency and ownership structures may cap margins and create a sustained overhang on the PBM model.
Jefferies' stance reflects a view that, despite an apparently cheap multiple, Cigna faces a confluence of operational and regulatory uncertainties that could weigh on earnings and limit multiple expansion through 2027.